CYREN

Across TCGA pan-cancer cohorts, CYREN mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CYREN data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CYREN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CYREN expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC and PDAC are the cancer types where CYREN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	1.000	0.776	.011	9	view →
PDAC	DFS	Median	All	0.554	0.791	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CYREN–LSCC (OS)

Open the LSCC breakdown →